{"name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","slug":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","ticker":"","exchange":"","domain":"daiichisankyoeuropegmbhadaiichisankyocompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"VKA-Based Regimen","genericName":"VKA-Based Regimen","slug":"vka-based-regimen","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"Olmesartan medoxomil tablets high dose","genericName":"Olmesartan medoxomil tablets high dose","slug":"olmesartan-medoxomil-tablets-high-dose","indication":"Hypertension","status":"phase_3"},{"name":"Perindopril + amlodipine + if necessary, hydrochlorothiazide","genericName":"Perindopril + amlodipine + if necessary, hydrochlorothiazide","slug":"perindopril-amlodipine-if-necessary-hydrochlorothiazide","indication":"Hypertension (essential hypertension in patients not adequately controlled on dual therapy)","status":"marketed"},{"name":"Olmesartan medoxomil tablets low dose","genericName":"Olmesartan medoxomil tablets low dose","slug":"olmesartan-medoxomil-tablets-low-dose","indication":"Hypertension","status":"marketed"},{"name":"losartan + hydrochlorothiazide, if necessary","genericName":"losartan + hydrochlorothiazide, if necessary","slug":"losartan-hydrochlorothiazide-if-necessary","indication":"Hypertension","status":"phase_3"},{"name":"olmesartan medoxomil + hydrochlorothiazide, if necessary","genericName":"olmesartan medoxomil + hydrochlorothiazide, if necessary","slug":"olmesartan-medoxomil-hydrochlorothiazide-if-necessary","indication":"Hypertension (essential hypertension)","status":"marketed"},{"name":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","genericName":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","slug":"olmesartan-amlodipine-hydrochlorothiazide-if-necessary","indication":"Hypertension (essential hypertension in patients not adequately controlled on dual therapy)","status":"marketed"}]}],"pipeline":[{"name":"VKA-Based Regimen","genericName":"VKA-Based Regimen","slug":"vka-based-regimen","phase":"phase_3","mechanism":"VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation.","indications":["Atrial fibrillation for stroke prevention","Venous thromboembolism (DVT/PE) prevention and treatment","Mechanical heart valve thromboprophylaxis"],"catalyst":""},{"name":"Olmesartan medoxomil tablets high dose","genericName":"Olmesartan medoxomil tablets high dose","slug":"olmesartan-medoxomil-tablets-high-dose","phase":"phase_3","mechanism":"Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"Perindopril + amlodipine + if necessary, hydrochlorothiazide","genericName":"Perindopril + amlodipine + if necessary, hydrochlorothiazide","slug":"perindopril-amlodipine-if-necessary-hydrochlorothiazide","phase":"marketed","mechanism":"This combination reduces blood pressure by blocking angiotensin II formation (perindopril), relaxing blood vessel smooth muscle (amlodipine), and reducing fluid volume (hydrochlorothiazide).","indications":["Hypertension (essential hypertension in patients not adequately controlled on dual therapy)"],"catalyst":""},{"name":"Olmesartan medoxomil tablets low dose","genericName":"Olmesartan medoxomil tablets low dose","slug":"olmesartan-medoxomil-tablets-low-dose","phase":"marketed","mechanism":"Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"losartan + hydrochlorothiazide, if necessary","genericName":"losartan + hydrochlorothiazide, if necessary","slug":"losartan-hydrochlorothiazide-if-necessary","phase":"phase_3","mechanism":"Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure.","indications":["Hypertension","Chronic kidney disease"],"catalyst":""},{"name":"olmesartan medoxomil + hydrochlorothiazide, if necessary","genericName":"olmesartan medoxomil + hydrochlorothiazide, if necessary","slug":"olmesartan-medoxomil-hydrochlorothiazide-if-necessary","phase":"marketed","mechanism":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.","indications":["Hypertension (essential hypertension)"],"catalyst":""},{"name":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","genericName":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","slug":"olmesartan-amlodipine-hydrochlorothiazide-if-necessary","phase":"marketed","mechanism":"This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways.","indications":["Hypertension (essential hypertension in patients not adequately controlled on dual therapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQVm4yUEp1QnpHNTVfSmE4cUNsN2J2MkVtMkRoOHdkRDg3dkdWNmlHa2loei1NTUwzR0VfYkdOd0taQlA2YWVueTZGa2NDM0NBZTNEa0c2U0dkZ2JTU2t2eXlKVDZheGpzaHpqM3RIN2U3THNUQzJtSy11d3JDNHQ2OGF0cXR6cDZqSUp2R2tIcVA5bHROWkh2ZkZEQW96NzVsRlRBaXNFa1MzX3JwRjdqdDhOLTFOYmx0RUxqbA?oc=5","date":"2026-03-16","type":"pipeline","source":"AD HOC NEWS","summary":"Daiichi Sankyo Co Ltd Stock (ISIN: JP3475350009) Faces Headwinds Amid Oncology Pipeline Pressures - AD HOC NEWS","headline":"Daiichi Sankyo Co Ltd Stock (ISIN: JP3475350009) Faces Headwinds Amid Oncology Pipeline Pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOVUpIQjZFNFZ5RTBPSENNQ19mZ0pka3Y5Unk4aDEtRXlCQkxZZUpvYm1KWEhLbUUteFNYZ1BnRmNtZkpaZ2pMYmVvNjRjdjBJMmVveDRaTjQ2LVN1SmpuaUZzS1hCZUdMVWhDVjdQNl84Mko0dUExMXpuQXVadnpQMldCZHBqUlV2Q2stcVRoQW1zYWd1MWFNRVMwSVR0Y3Q3M1BqRVNoMkFLUlVxdUNTMm1mTkhCUTZxUmp0amhuWHljTVgwcnRjOFE2TVdON3o5SkZGWWJ2ODN4QllpSWhLWHlSVHpTWmpMZ3FNb0M2ZXA1N2RYV19vRFNFaDJxUndIZUZCblJvY0NVTFRMRERKNXh4WWkza1pCSXR2OVVwNW95Zw?oc=5","date":"2026-03-05","type":"deal","source":"businesswire.com","summary":"GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. - businesswire.com","headline":"GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNN0FGU1hYN3dNcWpRTUtRR0Q1QnRKMmNNWGVyVFoyS0cwaDVNaTlaUFhhendWU21yY2ZpZV9wY1B1ajFUSG0zVi1CN0h0NXhKaDZObFNtMGN1V3FPTHEtX3A1NEV3VXhZdVRTSm5aaGNGQXExTnRJWkppUTJPdnFybXpJa3I2T2VoQzRkZi1Dc25qNFhHWXp1clhnX25XcUU1OVBRMG5kNmlKV0NFOTdONVA4R1NJUQ?oc=5","date":"2026-02-20","type":"pipeline","source":"European Pharmaceutical Review","summary":"Daiichi Sankyo picks Dr John Tsai to head up R&D - European Pharmaceutical Review","headline":"Daiichi Sankyo picks Dr John Tsai to head up R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOV3FzLUV1MGpxVk83Q1Z3LVd4STZVX3hPS1lDYVFMM1dWYmk4TUs4NWlOQkxJVDBXZDdleWdJV2NRZWlOZ3JXU01RUjhoaF9WX21MdlV1dGZIa0Y3NkNsX2NScm9oRml3bm51VkJSMm9HNVR0YXB6alB5S2J1QkhJQzJtQ2laamdOamZuOWxDRlhJM2NBQlBTdm5fSmhFMXY3SzRZUng2d3Y4MnEwYXZuMG43MDRYYjhZdXc?oc=5","date":"2026-01-26","type":"pipeline","source":"Fierce Pharma","summary":"Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance - Fierce Pharma","headline":"Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQb2xfYV9YYnE5NTNuWEZjZV95TU5McFVuOC1tWTJSNEhLTS1HSEJtTEUtWVpNbzhtU2ExOWNfSk1QM0NEVzgwcHkxdUUzZDJ0eXBkcFhYdFB6a1NFMmpVUl9iNmZaNmZEcl85NnRHNHdDM1VMeDl4VnFwcVNEdzh5V2FCamtQSXNxMnZjUUZSYVNyMGxZdzlxTzhvMUt4R1Iwd3hYeTVwLUE?oc=5","date":"2026-01-23","type":"pipeline","source":"The Pharma Letter","summary":"Daiichi Sankyo appoints new head for European research center - The Pharma Letter","headline":"Daiichi Sankyo appoints new head for European research center","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQOWZnSF9WaEN2TWRQUHZkSmc3Um5VaEk0c2NMamNhSl9oZWJPSUZnSUVjcUdlbU4xUzZtdFZIelQ3V0hhV0RWUWM3UGp3U216bEJGWlhIU19oRE5BOVp0Umx1dEY5Z1JSY25fOUtXS0NSWlk3Y2wwU2dKMVNvN1h4dHU4QXVFYWhiWFRJMERoTkpZTmlwOVRXMjA5YUtQQ3lyLTdvZXNZN3o5OXlXcHZ1OUpLUGIwbmxNSmlMZUw5MG8yMEdnLTlrWndSekhkNnhWbWdnZTdZX0dRajlobERRRVpuWnJ0bG44anZfZnJQZDBJeWlKY29ua3ViMmFYUUhKNXB0djhiRkk?oc=5","date":"2026-01-07","type":"pipeline","source":"businesswire.com","summary":"Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA - businesswire.com","headline":"Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPOFpjQ2gxLWpPdk51NXVETlJjanFUc3ZtOWp6cmR1TkR1OTg0czdFTkxZSVNXRVlDWWZHRHFkRXRCcTBlRGUtUkd5ZEowVWZGV2d6YlFKdFJqR3ppZkVUVUh6dWdVQXlaOVRkZWd6YV9jN2RhTTJpYm55Ty13d2g0RWQza0pjWUVibkxYWDFhaFJyemRUdU5EQTQwS19BeS02d3lvTy1zdHVOSzRHT3VjR05RTVFzSlpiWTZLYk5zS3d5aFprZncxYUJUM0E2bDVTMUxxZmpuZ19UQUN4OUE?oc=5","date":"2025-08-13","type":"trial","source":"Emerj Artificial Intelligence Research","summary":"AI as Enterprise-Wide Enabler of Clinical Trial Innovation - with Leaders from Medable, Takeda, Sanofi, Novartis, and Daiichi Sankyo - Emerj Artificial Intelligence Research","headline":"AI as Enterprise-Wide Enabler of Clinical Trial Innovation - with Leaders from Medable, Takeda, Sanofi, Novartis, and Da","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE8xNnpKSEt0Qk51X0RTbTdhNFBmdlpJQ3lpWlN5VnZZNE95WXhBMmJwMGp0TzhBWjVkMWlsVHdFaDNJbGxMYUtOalpSWjVLUjB4WnRWa0M1OTJuN3hvOHVIeHBuRFh5UWc?oc=5","date":"2025-05-22","type":"pipeline","source":"Cleanroom Technology","summary":"High-tech for the future - Cleanroom Technology","headline":"High-tech for the future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQeEUxNTZTY3BhYWpvYmUwTjVhTk9aLVdCdUFIVUNVWWhWZEtheGQzUS1NckFSZ0VENEFLeWp2dHd3LXdrWnRfRzRYaHBJVkRuWDlUT194eXRzZS1neXB3QzlvcXRDaFNNTDBsNkc4cGJJMlJQMV95ZHRnRGtneXNxaFp4N3U2cXgtR0VvZlBDYkpjdENDVUhmVkRMQVdJVFpfejk2QTdjM2s4RnhYdHpyelhwUVFXcE45alg2dU1iRjZQaUpwLXpJNlh2aG5FZGtKajZiRWVtSzVJVDBW?oc=5","date":"2024-02-22","type":"pipeline","source":"BioPharm International","summary":"Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs - BioPharm International","headline":"Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPem56bFFYOUdYXy1KUm5ocW1GejdmdnZWNURHOHN3a3dhYzhIVEdPcDZpSHMzRTFhYVc4V1NMZ0MyWE00WGFIX2tuVFhSZmZNcmY2Z1FGSnU0cmRrRndwQ0pZTEt5SjJTd296Nmd3QzFaRWRoLTFtVTltdjdIdVpmTFFWMnRmcXFqemdxMGpWRHVEbmN0aE1TckYzYTUwRDNiRlR0T3JJajBzcktJaDVHLXhOMHRwZm5BUE82NjlJdDB5RjhfM0p0TGk2RVZPSFhSX2c?oc=5","date":"2024-01-08","type":"deal","source":"DBusiness Magazine","summary":"Ann Arbor-based Esperion Therapeutics Reaches $125M Deal with Daiichi Sankyo Europe - DBusiness Magazine","headline":"Ann Arbor-based Esperion Therapeutics Reaches $125M Deal with Daiichi Sankyo Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZW5CRnJ0dWF6TFVTVkU5N3hLbWpSRHUydVo1SGViaDZOQS1LNktBSUVlV0tDQlp3QXZjeEVFYkRFaTJab3AxaVlGdWNRUVFaMTRWZ21KbjJ5RF9fZi12TkhScm9KRmNmeXp4TnFiT3NjOEY1WXdkVUpfbWtfdEZiRDI0QjVJUkdkUWp1MjVyajVYMnluZ1pycV83c0U0VGdxWjFwLWFfZk9zVURnNHhfR1FMSHlIc2VOTWJJ?oc=5","date":"2023-11-07","type":"pipeline","source":"BioSpectrum Asia","summary":"Masahiro Kato steps in as Managing Director of Daiichi Sankyo Europe - BioSpectrum Asia","headline":"Masahiro Kato steps in as Managing Director of Daiichi Sankyo Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaUF3ekdXVURBT2VwYkI3UVNyU3R3b3d1ZXlLcEZaeEhEUXVESUIzUE5VMjhxQUlicldzSGJFZmwwZEZFd2lHeWFpMkt1bkFXZTctSEhyUmtJdlE1bGdjbkdtTVRkR1pHOGJjaTdHZ3ZwNmdNRnpBLWN5QmhPWWJnNEctRVBOSW5nWGJHZ0ZzT0U1bUhwdFRKYi1MSThLanFnVDFYWktiM2JaeWM?oc=5","date":"2018-06-20","type":"pipeline","source":"European Medical Journal","summary":"The Innovation, Care, and Compassion of Daiichi Sankyo – Part 1 - European Medical Journal","headline":"The Innovation, Care, and Compassion of Daiichi Sankyo – Part 1","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":3,"marketed":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}